Dr. Michael Liebman

Dr. Liebman has more than 32 years’ experience in the world of medicine, biomedical research, and education. He is currently the managing director of IPQ Analytics and Strategic Medicine, which provides risk assessment solutions and decision analytics to the life sciences and healthcare.

He has held roles at the University of Pennsylvania Cancer Center, Roche Pharmaceuticals, Wyeth Pharmaceuticals, and Vysis. He co-founded Prosanos (now United BioSource), and previously served as executive director of the Windber Research Institute (now Chan Soon-Shiong Institute for Molecular Medicine).

He is an advisor on digital health and quantum computing and serves as a director of the Nathaniel Adamczyk Foundation in Pediatric ARDS. He is chair of the Informatics Program and Translational Medicine and Therapeutics for the PhRMA Foundation, and is a member of its scientific advisory board.

He also teaches as professor of Pharmacology and Physiology/Biophysics at Mount Sinai School of Medicine, Drexel College of Medicine, First Hospital of Wenzhou Medical University, and Fudan University. He also serves on the advisory board of many organizations and committees.

He received his Bachelor of Science in Physical Chemistry from Drexel University and Ph.D. in Physical Chemistry and Protein Crystallography from Michigan State University.